Medicare Part D Coverage and Costs for Glucagon-Like Peptide-1 Receptor Agonists

This cross-sectional study examines Medicare Part D coverage and out-of-pocket costs for glucagon-like peptide-1 receptor agonists following implementation of the Inflation Reduction Act.

Corresponding Author: Matthew J. Klebanoff, MD, MSHP, University of Pennsylvania Perelman School of Medicine, 423 Guardian Dr, Office 1313, Philadelphia, PA 19104 (matthew.klebanoff@pennmedicine.upenn.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.